HongKong:1672

Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41

SHANGHAI, Jan. 11, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the positive phase I clinical results of ASC41 oral ...

2021-01-12 08:30 817

First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial

SHANGHAI, Dec. 28, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announces today dosing of first subject with its NASH drug candidate ASC42, a Farnesoid X Receptor (F...

2020-12-28 08:30 2250

Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial

SHANGHAI, Dec. 22, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announces today dosing of overweight and obese subjects in a Phase Ib trial of ASC41, an oral tablet,...

2020-12-22 19:18 1594

Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist

SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that it received Fast Track designation from the U.S. Food and Drug Administration (F...

2020-12-14 08:30 1403

Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study

HANGZHOU and SHAOXING, China, Dec. 4, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolima...

2020-12-04 08:00 1916

Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer

SHANGHAI, Nov. 30, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that Melissa Palmer, MD, an internationally renowned Hepatologist, will join the Compa...

2020-11-30 08:00 1238

ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China

SHANGHAI and SAN FRANCISCO, Nov. 19, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and Sagimet Biosciences Inc. jointly announced today that they have completed patient enrollment in the ASC40 (TVB-2640) Phase 2 NASH trial inChina. The tr...

2020-11-19 08:30 1565

Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH

HANGZHOU, China and SHAOXING, China, Nov. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that the board of directors of the Company (the "Board") resolved to change the use of the remaining Net Proceeds from the Global Offering. (see announcement: https://www....

2020-11-18 17:00 5012

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist

SHANGHAI, Oct. 12, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic ste...

2020-10-12 08:30 7067

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist

SHANGHAI, Oct. 11, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic ste...

2020-10-12 08:30 6620

Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist

SHANGHAI, Sept. 14, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that it has filed investigational new drug application (IND) with US FDA for its non-alcoholic steatohepatitis (NASH) drug candidate ASC42. ASC42 is an in-...

2020-09-14 08:30 2174

Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)

SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement aiming at combination therapy of ASC41 ...

2020-09-09 18:30 2645

Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen

HANGZHOU and SHAOXING, China, Aug. 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech. ASC18 FDC co...

2020-08-20 20:00 2681

First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU, China and SHAOXING, China, Aug. 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody. ASC22(Envafolimab) Phase IIa clin...

2020-08-17 08:30 2470

Ascletis' All-oral HCV Treatment Approved for Marketing in China

HANGZHOU and SHAOXING, China, July 31, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its all-oral HCV treatment has been approved for marketing inChina by National Medical Products Administration (NMPA). The Company's all-oral HCV treatment (RDV/DNV Regimen) is ...

2020-07-31 08:47 7992

Bridging Study in China Completed for NASH Drug Candidate ASC40

HANGZHOU and SHAOXING, China, July 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis (NASH) drug candidate ASC40 (TVB-2640) in 34 Chinese subjects has been completed and data indicate...

2020-07-20 08:30 3350

ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial

HANGZHOU, China and SHAOXING, China, June 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its partner Sagimet Biosciences Inc (Sagimet, formerly 3-V Biosciences Inc), announced today positive results on oral, once-daily non-alcoholic steatohepatitis (NASH) dru...

2020-06-17 20:30 1980

Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication

HANGZHOU, China and SHAOXING, China, May 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from China's National Medical Products Administration (NMPA) for its in-house developed Category 1 Drug ASC41 to conduct clinical trials for Non-al...

2020-05-13 18:30 1809

Ascletis Receives IND Approval for its HIV Drug ASC09F

HANGZHOU and SHAOXING, China, April 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from National Medical Products Administration (NMPA) for its human immunodeficiency virus (HIV) protease inhibitor ASC09F (ASC09/Ritonavir Fixed-Dose C...

2020-04-13 20:00 1788

Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020

HANGZHOU and SHAOXING, China, April 1, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its partner Sagimet Biosciences (formerly 3-V Biosciences, Inc), will present clinical and preclinical data on non-alcoholic steatohepatitis (NASH) drug candidate TVB-2640 (Ascl...

2020-04-01 08:30 1670
123